secwatch.observer — SEC 8-K summary
======================================

Issuer:     ENANTA PHARMACEUTICALS INC (ENTA)
CIK:        0001177648
Form:       8-K
Filed at:   2021-08-05T23:59:59+00:00
Accession:  0001564590-21-041571
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Enanta reports Q3 fiscal 2021 net loss of $24.0M; nominates COVID-19 protease inhibitor EDP-235
--------------------------------------------------------------------------------

- Royalty revenue $21.6M from AbbVie's HCV regimen; net loss $24.0M ($1.19/sh) vs loss $14.3M ($0.71/sh) year ago.
- Cash and securities $372.5M; R&D expenses increased to $47.0M from $34.7M.
- Nominated EDP-235 oral protease inhibitor for SARS-CoV-2; Phase 1 study planned for early 2022.
- Positive Phase 1b data for EDP-514 in viremic HBV patients: mean HBV DNA reduction 3.3 logs.
- Planned retirement of CMO Nathalie Adda, M.D. in February 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1177648/000156459021041571/0001564590-21-041571-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1177648/000156459021041571/enta-8k_20210805.htm
  HTML page:      https://secwatch.observer/filing/0001564590-21-041571

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer